Article
DSP rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study.
Therapeutic advances in respiratory disease - 1 Jan 2000
Doubkova Martina, Kriegova Eva, Littnerova Simona, Schneiderova Petra, Sterclova Martina, Bartos Vladimir, Plackova Martina, Zurkova Monika, Bittenglova Radka, Lostaková Vladimira, Siskova Lenka, Lisa Pavlina, Suldova Hana, Doubek Michael, Psikalova Jana, Snizek Tomas, Musilova Pavlina, Vasakova Martina
Abstract excerpt
BACKGROUND: The antifibrotic drugs nintedanib and pirfenidone are used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the association of common profibrotic polymorphisms in MUC5B (mucin 5B, rs35705950) and DSP (desmoplakin, rs2076295) on antifibrotic treatment outcomes in IPF. METHODS: MUC5B rs35705950 and DSP rs2076295 were assessed in IPF patients (n = 210, 139 men/71 women) from the...